These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21691743)

  • 21. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.
    Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Selva-O'Callaghan A; Solans-Laqué R; Vilardell-Tarrés M
    Clin Rheumatol; 2011 Nov; 30(11):1393-8. PubMed ID: 21881859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
    Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
    Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Barnes H; Ghazipura M; Herman D; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Jan; 21(1):122-135. PubMed ID: 37772975
    [No Abstract]   [Full Text] [Related]  

  • 26. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
    Tzelepis GE; Plastiras SC; Karadimitrakis SP; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2007; 25(5):734-9. PubMed ID: 18078622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.
    White B; Moore WC; Wigley FM; Xiao HQ; Wise RA
    Ann Intern Med; 2000 Jun; 132(12):947-54. PubMed ID: 10858177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.
    Fraticelli P; Gabrielli B; Pomponio G; Valentini G; Bosello S; Riboldi P; Gerosa M; Faggioli P; Giacomelli R; Del Papa N; Gerli R; Lunardi C; Bombardieri S; Malorni W; Corvetta A; Moroncini G; Gabrielli A;
    Arthritis Res Ther; 2014 Jul; 16(4):R144. PubMed ID: 25007944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide.
    Abhishek A; Yazdani R; Pearce F; Regan M; Lim K; Hubbard R; Lanyon P
    Clin Rheumatol; 2011 Aug; 30(8):1099-104. PubMed ID: 21484227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
    Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
    Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
    J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
    Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
    Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
    Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.
    Roth MD; Tseng CH; Clements PJ; Furst DE; Tashkin DP; Goldin JG; Khanna D; Kleerup EC; Li N; Elashoff D; Elashoff RM;
    Arthritis Rheum; 2011 Sep; 63(9):2797-808. PubMed ID: 21547897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.